BGNE
BGNE Real Time Price USDRecent trades of BGNE by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in BGNE holdings by institutional investors
Quarterly net insider trading by BGNE's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$230,000 Oct 20, 2025 Issue: Health Issues
-
$220,000 Jul 21, 2025 Issue: Health Issues
-
$250,000 Apr 21, 2025 Issue: Health Issues
-
$170,000 Jan 24, 2025 Issue: Health Issues
-
$160,000 Oct 20, 2024 Issue: Health Issues
-
$160,000 Jul 22, 2024 Issue: Health Issues
-
$240,000 Apr 22, 2024 Issue: Health Issues
-
$140,000 Jan 22, 2024 Issue: Health Issues
-
$170,000 Oct 20, 2023 Issue: Health Issues
-
$90,000 Apr 20, 2022 Issue: Health Issues
-
$80,000 Jan 20, 2022 Issue: HEALTH ISSUES
-
$80,000 Oct 20, 2021 Issue: HEALTH ISSUES
-
$80,000 Jul 19, 2021 Issue: HEALTH ISSUES
-
$80,000 Apr 20, 2021 Issue: HEALTH ISSUES
-
$80,000 Jan 20, 2021 Issue: None
-
$40,000 Oct 20, 2020 Issue: None
-
$20,000 Jul 20, 2020 Issue: Health Issues
-
$50,000 Apr 17, 2020 Issue: Health Issues
BGNE Estimated quarterly lobbying spending
BGNE Revenue by Segment or Geography
New BGNE patent grants
-
Patent Title: Cyclic dinucleotides as sting agonists Oct. 07, 2025
-
Patent Title: Bcl-2 inhibitor Apr. 29, 2025
-
Patent Title: Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist Apr. 22, 2025
-
Patent Title: 3-[(1h-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof Jan. 14, 2025
-
Patent Title: Anti-ox40 antibodies and methods of use Oct. 01, 2024
-
Patent Title: Bcl-2 inhibitors Sep. 03, 2024
-
Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3kδ inhibitors Feb. 20, 2024
-
Patent Title: Interoperable platform for reducing redundancy in medical database management Jan. 16, 2024
-
Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3k δ inhibitors Aug. 15, 2023
-
Patent Title: Interoperable platform for reducing redundancy in medical database management Apr. 25, 2023
-
Patent Title: Immunotherapy for hepatocellular carcinoma Mar. 07, 2023
-
Patent Title: Crystalline forms of (s)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof Jan. 17, 2023
-
Patent Title: Anti-pd-l1 antibodies and their use as therapeutics and diagnostics Nov. 29, 2022
-
Patent Title: Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist Oct. 18, 2022
-
Patent Title: Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases Oct. 18, 2022
-
Patent Title: Bcl-2 inhibitors Aug. 23, 2022
-
Patent Title: Interoperable platform for reducing redundancy in medical database management Jul. 19, 2022
-
Patent Title: Btk inhibitors with improved dual selectivity Jul. 05, 2022
-
Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors Jan. 11, 2022
-
Patent Title: Anti-tigit antibodies and their use as therapeutics and diagnostics Jan. 04, 2022
-
Patent Title: Anti-tim-3 antibodies and use thereof Dec. 21, 2021
-
Patent Title: Treatment cancers using a combination comprising parp inhibitors Dec. 21, 2021
-
Patent Title: Imidazo[1,5-a]pyrazine derivatives as pi3k δ inhibitors Oct. 05, 2021
-
Patent Title: Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof Jan. 26, 2021
-
Patent Title: 5 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases Jan. 05, 2021
-
Patent Title: Combination of a pd-1 antagonist and a raf inhibitor for treating cancer Dec. 15, 2020
-
Patent Title: 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases May. 12, 2020
-
Patent Title: Fused tricyclic compounds as raf kinase inhibitors Mar. 03, 2020
-
Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Feb. 18, 2020
-
Patent Title: Anti-pd-l1 antibodies and their use as therapeutics and diagnostics Jan. 28, 2020
-
Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Dec. 10, 2019
-
Patent Title: Process for preparing a parp inhibitor, crystalline forms, and uses thereof Oct. 29, 2019
-
Patent Title: Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore Jul. 16, 2019
-
Patent Title: 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases May. 07, 2019
-
Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Feb. 19, 2019
-
Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Mar. 20, 2018
-
Patent Title: Fused tricyclic compounds as raf kinase inhibitors Feb. 20, 2018
-
Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics Dec. 05, 2017
-
Patent Title: Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones Nov. 28, 2017
-
Patent Title: Fused tricyclic amide compounds as multiple kinase inhibitors Jun. 06, 2017
-
Patent Title: Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Jun. 06, 2017
-
Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Apr. 11, 2017
-
Patent Title: Substituted imidazo[1,2-b]pyrazoles as bruton's tyrosine kinase modulators Jan. 31, 2017
-
Patent Title: Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators Sep. 20, 2016
-
Patent Title: Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones Jul. 19, 2016
-
Patent Title: Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as parp inhibitors May. 03, 2016
-
Patent Title: Fused tricyclic compounds as raf kinase inhibitors Mar. 01, 2016
-
Patent Title: Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors Feb. 16, 2016
-
Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics Dec. 22, 2015
-
Patent Title: Anti-pd1 antibodies and their use as therapeutics and diagnostics May. 27, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded to BGNE from public contracts
Recent insights relating to BGNE
Recent picks made for BGNE stock on CNBC
ETFs with the largest estimated holdings in BGNE
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BGNE stock a Buy, Sell, or Hold?
- What is the price target for $BGNE stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BGNE stock?
- Who owns the most shares of $BGNE stock?
- What funds own $BGNE stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BGNE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
No description available